MX388684B - Metodo de administracion de compuestos donadores de nitroxilo. - Google Patents

Metodo de administracion de compuestos donadores de nitroxilo.

Info

Publication number
MX388684B
MX388684B MX2019008000A MX2019008000A MX388684B MX 388684 B MX388684 B MX 388684B MX 2019008000 A MX2019008000 A MX 2019008000A MX 2019008000 A MX2019008000 A MX 2019008000A MX 388684 B MX388684 B MX 388684B
Authority
MX
Mexico
Prior art keywords
administration
donor compounds
nitroxyl donor
compounds
nitroxyl
Prior art date
Application number
MX2019008000A
Other languages
English (en)
Spanish (es)
Other versions
MX2019008000A (es
Inventor
Elyse G Stock
Maria Borentain
Paul D Kessler
Tushar Garimella
William R Ewing
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of MX2019008000A publication Critical patent/MX2019008000A/es
Publication of MX388684B publication Critical patent/MX388684B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
MX2019008000A 2017-01-03 2018-01-02 Metodo de administracion de compuestos donadores de nitroxilo. MX388684B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762441803P 2017-01-03 2017-01-03
US201762549932P 2017-08-24 2017-08-24
PCT/US2018/012114 WO2018128999A1 (en) 2017-01-03 2018-01-02 Method of administering nitroxyl donating compounds

Publications (2)

Publication Number Publication Date
MX2019008000A MX2019008000A (es) 2019-11-05
MX388684B true MX388684B (es) 2025-03-20

Family

ID=61224497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008000A MX388684B (es) 2017-01-03 2018-01-02 Metodo de administracion de compuestos donadores de nitroxilo.

Country Status (12)

Country Link
US (1) US11083704B2 (https=)
EP (1) EP3565544A1 (https=)
JP (1) JP2020503356A (https=)
KR (1) KR20190103281A (https=)
CN (1) CN110520116A (https=)
AU (1) AU2018205621B2 (https=)
BR (1) BR112019013702A2 (https=)
CA (1) CA3049003A1 (https=)
IL (1) IL267728A (https=)
MX (1) MX388684B (https=)
SG (2) SG10202107533RA (https=)
WO (1) WO2018128999A1 (https=)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024524A (en) 1910-08-06 1912-04-30 Lanston Monotype Machine Co Type-casting machine.
US1058314A (en) 1911-02-20 1913-04-08 B F Cummins Company Separating mechanism for mail-matter.
US1048704A (en) 1911-04-29 1912-12-31 King Construction Company Clip for connecting rafters, purlins, and sash-bars of greenhouses.
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US1051784A (en) 1912-02-16 1913-01-28 Martin Trewhitt Brooder.
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
CA2554771A1 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
EP1909779A1 (en) 2005-06-23 2008-04-16 Johns Hopkins University Thiol-sensitive positive inotropes
BRPI0708804B8 (pt) 2006-03-17 2021-05-25 Cardioxyl Pharmaceuticals Inc compostos derivados de n-hidroxilsulfonamida como doadores de nitroxil, composição farmacêutica e kit
EP2010476A4 (en) 2006-04-13 2011-01-26 Univ Wake Forest Health Sciences NITROXYL DISPENSERS FROM C-NITROSO COMPOUNDS
NZ584036A (en) 2007-09-26 2012-06-29 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
LT2278975T (lt) 2008-05-07 2016-11-25 Cardioxyl Pharmaceuticals Inc. Nauji nitrozo junginiai kaip nitroksilo donorai, ir jų panaudojimo būdas
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
US20110144067A1 (en) 2009-12-07 2011-06-16 Toscano John P N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives
WO2011071947A2 (en) 2009-12-07 2011-06-16 Johns Hopkins University Bis-acylated hydroxylamine derivatives
AU2013201929B2 (en) 2011-10-17 2015-07-23 The Johns Hopkins University N-substituted hydroxylamine derivatives with carbon-based leaving groups
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
HRP20180121T1 (hr) 2013-01-18 2018-02-23 Cardioxyl Pharmaceuticals Inc. Donori nitroksila s poboljšanim terapijskim indeksom
EP2764868A1 (en) * 2013-02-08 2014-08-13 Friedrich-Alexander-Universität Erlangen-Nürnberg Combination of nitroprusside and a sulfide salt as an HNO-releasing therapeutic for the treatment or prevention of cardiovascular diseases
US20160008394A1 (en) * 2013-02-28 2016-01-14 Aires Pharmaceuticals, Inc. Inorganic nitrite to improve cardiopulmonary hemodynamics
EP2833611A1 (en) 2013-07-31 2015-02-04 Airbus Operations GmbH Method of transmitting speech and digital data via an analog speech channel
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US10730828B2 (en) 2015-10-19 2020-08-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
KR20180063326A (ko) 2015-10-19 2018-06-11 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 피라졸론 유도체
US10913728B2 (en) 2016-07-28 2021-02-09 The Johns Hopkins University O-substituted hydroxamic acids

Also Published As

Publication number Publication date
AU2018205621B2 (en) 2023-01-05
IL267728A (en) 2019-08-29
MX2019008000A (es) 2019-11-05
US20190343790A1 (en) 2019-11-14
US11083704B2 (en) 2021-08-10
AU2018205621A1 (en) 2019-08-01
WO2018128999A1 (en) 2018-07-12
BR112019013702A2 (pt) 2020-03-03
SG11201906145YA (en) 2019-08-27
CN110520116A (zh) 2019-11-29
SG10202107533RA (en) 2021-08-30
CA3049003A1 (en) 2018-07-12
JP2020503356A (ja) 2020-01-30
KR20190103281A (ko) 2019-09-04
EP3565544A1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
MX2017001512A (es) Compuestos activos hacia bromodominios.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2017006653A (es) Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión.
DK3684333T3 (da) Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
CR20180564A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen
MX2022005372A (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o mas estatinas.
MX2015009269A (es) Composiciones farmaceuticas que comprenden donadores de nitroxilo.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
MX390899B (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
EP3476864A4 (en) ETAR ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
BR112017004552A2 (pt) composições farmacêuticas
GB2543709A (en) Pharmaceutical agent
EA201700254A1 (ru) Комбинация
MX391400B (es) Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato.
MX388684B (es) Metodo de administracion de compuestos donadores de nitroxilo.
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола